Loading organizations...
Based in Philadelphia, Pennsylvania, Daymark Health is a value-based oncology company that provides supportive cancer care services, including interdisciplinary home-based interventions, telehealth programs, and integrated palliative care. The organization partners directly with health plans, hospitals, and independent oncologists to deliver evidence-based medical treatments under specialized value-based care contracts. Following its public launch, the enterprise began clinical operations by serving over 2,500 active patients through an initial partnership with a regional health payer in the Northeast United States. To further scale its clinical model, Daymark Health has secured $31.5 million in total venture capital financing, comprising an $11.5 million seed round and a $20 million Series A round backed by institutional investors such as Maverick Ventures, Yosemite, and Oncology Ventures. The healthcare company was officially founded in 2024 by Justin Bekelman, Rob Pahlavan, and Jonathan Rhodes.
Daymark Health has raised $32.0M across 2 funding rounds.
Daymark Health has raised $32.0M in total across 2 funding rounds.
Daymark Health has raised $32.0M in total across 2 funding rounds.
Daymark Health's investors include Kelsey Maguire, Aman Mahajan, MD, PhD, MBA, Alpha Venture Partners, Maverick Capital, Sandbox Industries, Oncology Ventures, Yosemite, Matt Bettonville, Gautam Gupta.
Daymark Health has raised $32.0M across 2 funding rounds. Most recently, it raised $20.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $20M Series A | Kelsey Maguire, Aman Mahajan, MD, Phd, MBA | Alpha Venture Partners, Maverick Capital, Sandbox Industries, Oncology Ventures, Yosemite | Announced |
| Apr 1, 2025 | $12M Seed | Maverick Capital, Matt Bettonville | Gautam Gupta, Alpha Venture Partners, Oncology Ventures | Announced |
Daymark Health is a Philadelphia-based cancer care company that builds a tech-enabled platform delivering personalized, hybrid virtual and in-home supportive care to cancer patients.[1][2][6] It serves cancer patients by partnering with health plans, oncologists, and primary care providers to address clinical, mental health, social, and symptom management needs through 24/7 navigation, support, and coordination—solving the fragmentation in oncology care outside clinic walls, where patients spend over 8,000 hours annually.[1][3][6] The company launched in April 2025 with an $11.5 million seed round and secured $20 million in Series A funding in September 2025, led by Healthier Capital with Blue Venture Fund, enabling scaling to thousands of patients and new partnerships, including with Blue Cross Blue Shield of Rhode Island.[1][2][3]
Daymark Health was co-founded by oncologist Dr. Justin Bekelman (CEO), who identified gaps in comprehensive cancer care amid advances in treatments but persistent system fragmentation.[1][2] The idea emerged to create a full-risk, value-based model integrating clinical, social, and mental health support virtually and in-home, launched in April 2025 with seed funding of $11.5 million led by Maverick Ventures and Yosemite, plus Oncology Ventures.[2][5] Early traction came from partnering with a major Northeast payer to serve over 2,500 patients, proving the model's viability in real-world oncology workflows.[2][5] The Series A in September 2025 accelerated growth, adding board members like Dr. Aman Mahajan from Healthier Capital.[1][3]
(Note: DaymarkSI.com [4] refers to a separate healthcare IT firm focused on data centers/AI/cloud, unrelated to Daymark Health's oncology platform.[4])
Daymark rides the oncology tipping point, where 2 million+ annual U.S. cases, specialty drug cost pressures, and payer demands for value-based care converge with patient preferences for home-based models post-earlier discharges.[1][2][3] Timing aligns with hospital-at-home growth and payer-provider alignment on integrated care, breaking silos to cut avoidable costs while boosting access/experience.[1][5] It influences the ecosystem by partnering with health plans (e.g., BCBS plans via Blue Venture Fund) and oncologists, scaling tech platforms that redefine supportive oncology amid fragmented systems—potentially setting standards as in-home cancer services rise.[2][3]
Daymark is poised to expand partnerships with more payers, invest in platform tech, and reach thousands amid oncology's shift to scalable, patient-first models.[3][5] Trends like AI-enhanced care coordination, full-risk contracts, and home health demand (especially for advanced cancers) will propel growth, with influence evolving toward national standards in value-based oncology.[1][2] As a well-funded innovator connecting clinic gaps, Daymark exemplifies tech's role in humanizing cancer journeys at scale.
